{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:22:34Z","timestamp":1795058554525,"version":"4.10.2"},"reference-count":42,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Malignancy-associated hemophagocytic lymphohistiocytosis (mHLH), a hyperinflammatory syndrome, has poor prognosis and no standard therapy. Emapalumab, a fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon gamma, is approved for treating primary hemophagocytic lymphohistiocytosis (pHLH). REAL-HLH, a retrospective chart review conducted across 33 US hospitals, evaluated real-world treatment patterns and outcomes in patients treated with \u22651 dose of emapalumab between 20 November 2018 and 31 October 2021. Data are presented for the subset of patients with mHLH. Overall, 51 of 105 (48.6%) patients were categorized as having secondary HLH, of which 17 of 51 patients had HLH associated with an underlying malignancy (mHLH). At HLH diagnosis, the median age (range) was 15.0 (3.0-27.0) years, 6 of 14 (42.9%) patients with available data had a positive Optimized HLH Inflammatory index, indicating pathologic inflammation; 9 of 17 (52.9%) had infections; and 10 of 17 (58.8%) received emapalumab in an intensive care unit. Emapalumab was primarily initiated for treating refractory (10\/17; 58.8%) or progressive (3\/17, 17.7%) disease. Most patients received HLH-related therapies before (16\/17; 94.1%) and\/or concurrent with (15\/17; 88.2%) emapalumab. Treatment with emapalumab-containing regimens normalized most key laboratory parameters and maintained normal values for others (fibrinogen [11\/13; 84.6%], absolute neutrophil count [6\/10; 60%], and chemokine ligand 9 [7\/8; 87.5%]) per physician assessment. Overall survival at the end of follow-up and 12-month survival probability from emapalumab initiation were 23.5% and 22.1%, respectively. In conclusion, emapalumab-containing regimens normalized, improved, or maintained normal values for most laboratory parameters in patients with mHLH. Future studies are warranted to establish appropriate emapalumab dosing and utility in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013690","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:59:36Z","timestamp":1764795576000},"page":"1564-1575","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-4427","authenticated-orcid":false,"given":"Adi","family":"Zoref-Lorenz","sequence":"first","affiliation":[{"name":"1Department of Medicine, Hematology Institute, Meir Medical Center, School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"2Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6625-739X","authenticated-orcid":false,"given":"Carl E.","family":"Allen","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4603-7963","authenticated-orcid":false,"given":"Edward M.","family":"Behrens","sequence":"additional","affiliation":[{"name":"4Division of Rheumatology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-9932","authenticated-orcid":false,"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[{"name":"5Division of Bone and Marrow Transplant, Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Chien","sequence":"additional","affiliation":[{"name":"6Department of Hematology-Oncology, Lucile Packard Children\u2019s Hospital at Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-2679","authenticated-orcid":false,"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[{"name":"7Department of Pediatric Hematology-Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-9377","authenticated-orcid":false,"given":"Ashley P.","family":"Hinson","sequence":"additional","affiliation":[{"name":"8Department of Pediatric Hematology-Oncology, Atrium Health, Levine Children\u2019s Hospital, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Intzes","sequence":"additional","affiliation":[{"name":"9Department of Pediatric Hematology-Oncology, Providence Sacred Heart Medical Center and Children\u2019s Hospital, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4790-9919","authenticated-orcid":false,"given":"Michael S.","family":"Isakoff","sequence":"additional","affiliation":[{"name":"10Center for Cancer and Blood Disorders, Connecticut Children\u2019s Medical Center, Hartford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-9390","authenticated-orcid":false,"given":"Jennifer W.","family":"Leiding","sequence":"additional","affiliation":[{"name":"11Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD"},{"name":"12Division of Allergy and Immunology, Institute for Clinical and Translational Research and the Cancer and Blood Disorders Institute, Johns Hopkins All Children\u2019s Hospital, St Petersburg, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-2491","authenticated-orcid":false,"given":"Abiola","family":"Oladapo","sequence":"additional","affiliation":[{"name":"13Sobi, Inc., Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Panigrahi","sequence":"additional","affiliation":[{"name":"14Division of Pediatric Hematology\/Oncology, University of California Davis Medical Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachit A.","family":"Patel","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0543-6677","authenticated-orcid":false,"given":"Priti","family":"Pednekar","sequence":"additional","affiliation":[{"name":"16PRECISIONheor, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6349-1869","authenticated-orcid":false,"given":"Anish K.","family":"Ray","sequence":"additional","affiliation":[{"name":"17Department of Pediatric Hematology-Oncology, Cook Children\u2019s Medical Center, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-2886","authenticated-orcid":false,"given":"Jennifer A.","family":"Rothman","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, Division of Pediatric Hematology-Oncology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-3627","authenticated-orcid":false,"given":"Blachy D\u00e1vila","family":"Salda\u00f1a","sequence":"additional","affiliation":[{"name":"19Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Walkovich","sequence":"additional","affiliation":[{"name":"20Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-9669","authenticated-orcid":false,"given":"Joanna","family":"Weinstein","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Oncology and Stem Cell Transplantation, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Yee","sequence":"additional","affiliation":[{"name":"13Sobi, Inc., Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[{"name":"2Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"22Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"23Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley P.","family":"Hinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olive S.","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo A.","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachit A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Intzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blachy D\u00e1vila","family":"Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Zoref-Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Tandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer W.","family":"Leiding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod K","family":"Gidvani-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Gloude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Bhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Riskalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brant","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026030915363039200_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2015.1.177","article-title":"Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis","volume":"2015","author":"Allen","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"2026030915363039200_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.blre.2014.03.002","article-title":"Hemophagocytic syndromes--an update","volume":"28","author":"Janka","year":"2014","journal-title":"Blood Rev"},{"issue":"15","key":"2026030915363039200_bib3","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026030915363039200_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2026030915363039200_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13462","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents","volume":"170","author":"Lehmberg","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"2026030915363039200_bib6","first-page":"997","article-title":"Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies","volume":"100","author":"Lehmberg","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2026030915363039200_bib7","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"17","key":"2026030915363039200_bib8","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2026030915363039200_bib9","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/cancers15061839","article-title":"Diagnosis and management of adult malignancy-associated hemophagocytic lymphohistiocytosis","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026030915363039200_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2013.097394","article-title":"Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy","volume":"99","author":"Delavigne","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2026030915363039200_bib11","first-page":"207","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey","volume":"51","author":"Celkan","year":"2009","journal-title":"Turk J Pediatr"},{"issue":"1","key":"2026030915363039200_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2026030915363039200_bib13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjh.16630","article-title":"Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review","volume":"189","author":"Dupr\u00e9","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2026030915363039200_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"key":"2026030915363039200_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"2026030915363039200_bib16","doi-asserted-by":"crossref","first-page":"e27400","DOI":"10.1002\/pbc.27400","article-title":"Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis","volume":"65","author":"Gurunathan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026030915363039200_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/pbc.20950","article-title":"Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis","volume":"50","author":"O'Brien","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"9927","key":"2026030915363039200_bib18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"2026030915363039200_bib19","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"issue":"35","key":"2026030915363039200_bib20","doi-asserted-by":"crossref","first-page":"59977","DOI":"10.18632\/oncotarget.19230","article-title":"A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2026030915363039200_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","article-title":"Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis","volume":"89","author":"Parikh","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"2026030915363039200_bib22","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/cncr.30084","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes","volume":"122","author":"Tamamyan","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"2026030915363039200_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.13837","article-title":"Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years","volume":"172","author":"Schram","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2026030915363039200_bib24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026030915363039200_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2026030915363039200_bib26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2026030915363039200_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","article-title":"Targeting interferon-gamma in hyperinflammation: opportunities and challenges","volume":"17","author":"De Benedetti","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2026030915363039200_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-013-1878-y","article-title":"IP-10\/CXCL10 and MIG\/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome","volume":"93","author":"Maruoka","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"2026030915363039200_bib29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cyto.2012.06.257","article-title":"P156 investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody","volume":"59","author":"Hatterer","year":"2012","journal-title":"Cytokine"},{"issue":"19","key":"2026030915363039200_bib30","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2026030915363039200_bib31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2026030915363039200_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv"},{"issue":"S1","key":"2026030915363039200_bib33","doi-asserted-by":"crossref","first-page":"e28077","DOI":"10.1002\/pbc.28077","article-title":"Abstracts from the 35th Annual Meeting of the Histiocyte Society, Memphis, TN, USA, November 3-5, 2019","volume":"67","author":"Bracaglia","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026030915363039200_bib34","first-page":"25","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharmaceut Med"},{"issue":"8","key":"2026030915363039200_bib36","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1080\/10428194.2017.1403018","article-title":"Clinical characteristics, therapy response, and outcome of 51 adult patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis: a single institution experience","volume":"59","author":"Lorenz","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026030915363039200_bib37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2026030915363039200_bib38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/10428194.2010.551153","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center","volume":"52","author":"Machaczka","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026030915363039200_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-4608(98)00203-9","article-title":"Development of acute lymphoblastic leukemia with translocation (4;11) in a young girl with familial pericentric inversion 12","volume":"110","author":"Goi","year":"1999","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2026030915363039200_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s12032-011-9963-3","article-title":"Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation","volume":"29","author":"Machaczka","year":"2012","journal-title":"Med Oncol"},{"issue":"11","key":"2026030915363039200_bib41","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/bloodadvances.2022007012","article-title":"Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis","volume":"7","author":"Gooptu","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026030915363039200_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1532\/IJH97.07012","article-title":"Nationwide survey of hemophagocytic lymphohistiocytosis in Japan","volume":"86","author":"Ishii","year":"2007","journal-title":"Int J Hematol"},{"issue":"9","key":"2026030915363039200_bib43","first-page":"2998","article-title":"Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis","volume":"109","author":"Johnson","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1564\/2506007\/blooda_adv-2024-013690-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1564\/2506007\/blooda_adv-2024-013690-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:36:42Z","timestamp":1773085002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1564\/556933\/Emapalumab-use-in-malignancy-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013690","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,26]]}}}